Precigen

PGENPhase 2

Germantown, United StatesFounded 2010precigen.com

Precigen is a biopharmaceutical company specializing in innovative precision medicines for diseases with high unmet need, particularly in immuno-oncology, autoimmune disorders, and infectious diseases. The company has achieved a significant milestone with the FDA approval of PAPZIMEOS (zopapogene imadenovec-drba) for recurrent respiratory papillomatosis. Its strategic direction is built on two core, proprietary technology platforms: AdenoVerse for adenovector-based gene therapies and UltraCAR-T for rapidly manufactured, multi-gene CAR-T cell therapies, aiming to increase patient access and improve outcomes.

Market Cap

$1.2B

Founded

2010

Focus

RNA & Gene TherapyCell & Gene Therapy

PGEN · Stock Price

USD 3.28+1.22 (+59.22%)

Historical price data

AI Company Overview

Technology Platform

Precigen's core technologies are the AdenoVerse platform, which uses proprietary gorilla adenovectors for gene delivery with large payload capacity and low seroprevalence, and the UltraCAR-T platform for rapid, non-viral manufacturing of multi-gene CAR-T cell therapies with enhanced persistence.

Pipeline Snapshot

8 drugs in pipeline

Drug	Indication	Stage
Zopapogene imadenovec (Zopa)	Recurrent Respiratory Papillomatosis	Approved
PRGN-2009 plus Pembrolizumab + Pembrolizumab alone	Cervical Cancer	Phase 2
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-201...	Recurrent Respiratory Papillomatosis	Phase 1/2
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - Hig...	Diabetes type1	Phase 1/2
INXN-4001	Heart Failure	Phase 1

Funding History

Total raised: $50.2M

Debt$50MUndisclosedAug 15, 2021

Grant$200KBill & Melinda Gates FoundationApr 15, 2020

Opportunities

Significant growth opportunities exist in leveraging the AdenoVerse platform for vaccines and immunotherapies in large infectious disease and oncology markets, and in applying the UltraCAR-T platform to overcome current limitations in treating solid tumors, a vast unmet need.

Strategic partnerships or out-licensing of its platforms could provide non-dilutive funding and accelerate development.

Risk Factors

Key risks include the commercial execution of its first product launch, the clinical validation of its novel technology platforms, intense competition in the gene and cell therapy space, and potential future capital needs to fund late-stage trials.

Competitive Landscape

Precigen competes with viral vector gene therapy companies and both autologous and allogeneic CAR-T developers. Its differentiation is based on the unique properties of its gorilla adenovectors (AdenoVerse) for repeat dosing and its rapid, non-viral manufacturing process designed to produce more persistent CAR-T cells (UltraCAR-T).

Publications

Patents

Pipeline